Our science
Leading the way with groundbreaking immunotherapies
Immunotherapy works by deploying antibodies to help the body’s immune system identify and destroy cancer and other diseases. At Y-mAbs, we are developing several strategies to guide the immune system for more precise and effective treatment.
Alongside monoclonal antibody therapies, Y-mAbs is researching, developing and optimizing other types of antibody-based therapies to potentially treat cancer and other diseases more effectively, including radioimmunotherapy. The principle for radioimmunotherapy is based on the specificity of monoclonal antibodies to target the tumor or disease cells. Subsequently, the radioactive payload irradiates the targeted tumor or disease cells for precise killing. Y-mAbs’ work develops both 1-step and 2-step antibody-based radioimmunotherapies.
Our pipeline
In addition to exploring additional indications for our commercial product, Y-mAbs is developing antibody-based therapies designed to address some of the most challenging diseases affecting children and young adults starting with cancers, including neuroblastoma and osteosarcoma, as well as adults, including small cell lung cancer, melanoma, and non-Hodgkin’s Lymphoma.
Study
Therapeautic Area
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
TRIAL SPONSOR
STATUS
Lead Programs
Naxitamab-gqgk (Anti-GD2)
201
Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
U.S. FDA Approved
12-230
Relapsed/Refractory High-Risk Neuroblastoma (Pediatric)
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
U.S. FDA Approved
BCC018
Front-Line Induction in High-Risk Neuroblastoma (Pediatric)
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Expect primary completion in 2026
15-096
Relapsed Second-Line Osteosarcoma
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Potential pivotal trial
17-251
Chemoimmunotherapy for Relapsed/Refractory High-Risk Neuroblastoma
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Study completed
Butterfly
Refractory Ewing’s Sarcoma
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Expect completion in 2028
Metastatic Breast Cancer
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Trial initiated in Q2 2024
SADA PRIT (Radioimmunotherapy)
1001
GD2-SADA: Solid Tumors (SCLC, Malignant Melanoma, Sarcoma)
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Ongoing Part A
1201
CD38-SADA: Non-Hodgkin Lymphoma
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Actively recruiting first patient
Early Programs
SADA PRIT (Radioimmunotherapy)
1002
GD2-SADA Neuroblastoma
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
Expected IND filing in 2024
HER2-SADA
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
B7H3-SADA
Preclinical
Phase I
PHASE II/Pivotal
APPROVED
SADA PRIT Technology Platform: Potentially transforming the future of radioimmunotherapy
Y-mAbs’ Self-Assembly-DisAssembly (SADA) Pre-targeted Radioimmunotherapy (PRIT) Technology Platform may have the potential to dramatically improve treatment outcomes for patients across a variety of cancers and diseases.
Clinical trial enrollment
To learn more about Y-mAbs’ open clinical trials and enrollment criteria, please visit Y-mAbs’ clinical trials page.